- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07649265
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
A Phase 1 Open-Label, Multicenter Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HBM7020 in Healthy Adult Participants and Adults With Seropositive Autoimmune Disease
This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020. The study will enroll healthy participants at low doses, followed by participants with moderate to severe autoimmune diseases with predominant B-cell involvement. Eligible participants include patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's disease (SjD), and rheumatoid arthritis (RA).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Otsuka Call Center
- Numéro de téléphone: 844-687-3522
- E-mail: otsukaprofessionalservices@otsuka-us.com
Lieux d'étude
-
-
Queensland
-
Brisbane, Queensland, Australie, 4006
- Recrutement
- Q-Pharm Pty Ltd
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Chercheur principal:
- Wong
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria for Healthy Participants (Part 1)
- Participants who are of non-childbearing potential or are using acceptable contraception.
- Body mass index (BMI) and body weight within an acceptable range.
- Good general health based on medical history, physical examination, electrocardiogram (ECG), and laboratory assessments.
Key Disease-Agnostic Inclusion Criteria for Patient Participants (Part 2)
- BMI and body weight within an acceptable range.
- Adequate hematologic, renal, hepatic, immunologic, and lymphocyte parameters.
Key Disease-Specific Inclusion Criteria for Patient Participants (Part 2)
-
Confirmed autoimmune disease with appropriate supporting autoantibody findings.
-
Stable background therapy prior to dosing.
-
Active moderate to severe disease consistent with protocol-defined disease activity criteria for:
- Systemic lupus erythematosus (SLE)
- Systemic sclerosis (SSc)
- Rheumatoid arthritis (RA)
- Sjögren's disease (SjD)
Key Inclusion Criteria for Rescreening Participants (Part 2)
- Meets Part 2 disease-agnostic inclusion criteria.
- Stable background autoimmune therapy prior to dosing.
- Ongoing active moderate to severe disease based on protocol-defined disease-specific criteria.
Key Exclusion Criteria for Parts 1 and 2
- Pregnant or breastfeeding participants.
- Recent vaccination within protocol-defined timelines.
- Clinically significant medical history or abnormal physical examination findings.
- Clinically significant cardiovascular abnormalities, including blood pressure, heart rate, syncope, or ECG findings.
- Prior or recent therapies or conditions that may interfere with study participation or safety evaluations.
- Severe pulmonary, renal, or cardiac disease, or clinically significant pulmonary hypertension.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part 1 and Part 2a Dose Escalation
Healthy participants and participants with seropositive systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), or Sjögren's disease (SjD) will receive HBM7020 in sequential dose-escalation cohorts during Part 1 and Part 2a, respectively. |
Liquid formulation, administered through intravenous infusion |
|
Expérimental: Part 2b
Eligible patients may receive optional retreatment of HBM7020 in Part 2b |
Liquid formulation, administered through intravenous infusion |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Discontinuations Due to Adverse Events Through Week 48
Délai: Up to Week 48
|
Up to Week 48
|
|
Number of Participants With Signs Characteristic of Cytokine Release Syndrome (CRS), Immune Related Reaction (IRR), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Including Immunosuppression-Related Infection
Délai: Up to Week 24
|
Up to Week 24
|
|
Number of Participants With Dose limiting AE Evaluation During Dose Escalation
Délai: Up to Day 15
|
Up to Day 15
|
|
Number of Participants With Clinically Significant Changes in Vital Signs
Délai: Up to Week 24
|
Up to Week 24
|
|
Number of Participants With Clinically Significant Changes in Physical Examination Findings
Délai: Up to Week 24
|
Up to Week 24
|
|
Change From Baseline in Serum High Sensitivity C-Reactive Protein (hsCRP)
Délai: Up to Week 20
|
Up to Week 20
|
|
Change From Baseline in Serum Erythrocyte Sedimentation Rate (ESR)
Délai: Up to Week 20
|
Up to Week 20
|
|
Change From Baseline in Serum Ferritin
Délai: Up to Week 20
|
Up to Week 20
|
|
Change From Baseline in Serum Immunoglobulin G (IgG)
Délai: Up to Week 20
|
Up to Week 20
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Area Under the Concentration-Time Curve From Time Zero to Last Observable Concentration (AUCt) of HBM7020
Délai: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC∞) of HBM7020
Délai: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Maximum Observed Plasma Concentration (Cmax) of HBM7020
Délai: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Time to Maximum Observed Plasma Concentration (tmax) of HBM7020
Délai: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Number of Participants With Anti-Drug Antibodies (ADA) to HBM7020
Délai: Up to Week 24
|
Up to Week 24
|
Collaborateurs et enquêteurs
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies musculo-squelettiques
- Maladies de la bouche
- Maladies stomatognathiques
- Arthrite
- Maladies articulaires
- Maladies rhumatismales
- Maladies du tissu conjonctif
- Maladies du système immunitaire
- Maladies oculaires
- Maladies de la peau
- Xérostomie
- Maladies des glandes salivaires
- Syndromes de sécheresse oculaire
- Maladies de l'appareil lacrymal
- Maladies de la peau et du tissu conjonctif
- Lupus érythémateux systémique
- Le syndrome de Sjogren
- Maladies auto-immunes
- Sclérodermie systémique
- Arthrite, rhumatoïde
Autres numéros d'identification d'étude
- 365-201-00001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Délai de partage IPD
Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Critères d'accès au partage IPD
Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .